Product Description
Mechanisms of Action: ADRB3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Overactive Bladder
Phase 1: Healthy Volunteers|Spinal Cord Injuries
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02256735 |
NCT02256735 | P1 |
Completed |
Healthy Volunteers |
2005-12-01 |
2024-11-27 |
Primary Endpoints |
|
NCT02256722 |
NCT02256722 | P1 |
Completed |
Healthy Volunteers |
2005-11-01 |
2019-03-20 |
Treatments |
|
NCT02259751 |
NCT02259751 | P1 |
Completed |
Spinal Cord Injuries |
2005-02-01 |
2019-03-20 |
Treatments |
|
NCT02259764 |
NCT02259764 | P1 |
Completed |
Healthy Volunteers |
2004-09-01 |
2019-03-20 |
||
NCT02259920 |
NCT02259920 | P1 |
Completed |
Healthy Volunteers |
2004-05-01 |
2019-03-20 |
Treatments |
|
NCT02259933 |
NCT02259933 | P1 |
Completed |
Healthy Volunteers |
2004-05-01 |
2019-03-20 |
Treatments |
|
NCT02259907 |
NCT02259907 | P1 |
Completed |
Healthy Volunteers |
2004-02-01 |
2019-03-20 |
Treatments |
|
2004-004590-28 |
2004-004590-28 | P2 |
Completed |
Overactive Bladder |
2005-06-30 |
2022-03-12 |
Treatments |
|
NCT00742833 |
KUC1203 | P2 |
Completed |
Overactive Bladder |
None |
2019-03-18 |
Treatments |
|
NCT01004315 |
KUC1301 | P3 |
Completed |
Overactive Bladder |
None |
2019-03-19 |
Treatments |
|
NCT01003405 |
KUC1302 | P3 |
Withdrawn |
Overactive Bladder |
None |
2019-03-19 |
Treatments |